Mahmoud Mehawed/LinkedIn
Sep 19, 2026, 00:48
Mahmoud Mehawed: Heparin vs Warfarin vs DOACs Understanding the Key Differences
Mahmoud Mehawed, Pharmacist at Innova Pharmacy, shared a post on LinkedIn:
“Heparin vs. Warfarin vs. DOACs
When managing thrombotic conditions, selecting the right anticoagulant requires balancing pharmacology, onset timing, monitoring parameters, and clinical safety profiles.
This comparative Venn diagram breaks down the key characteristics of three major anticoagulant classes:
- Heparin (UFH and LMWH):
Acts by activating antithrombin and provides rapid-onset anticoagulation via intravenous or subcutaneous administration. It is safe to use in pregnancy, requires PTT monitoring for unfractionated heparin, and carries risks such as bleeding and heparin induced thrombocytopenia (HIT).
- Warfarin:
Functions by inhibiting vitamin K epoxide reductase, suppressing clotting factors II, VII, IX, X, as well as proteins C and S. It features a slow onset requiring an initial bridge, demands routine PT INR monitoring, and has specific considerations including teratogenicity, skin necrosis risks, and reversal protocols using vitamin K and PCC.
- DOACs (Direct Oral Anticoagulants):
Comprise direct factor Xa or thrombin (IIa) inhibitors (such as apixaban, rivaroxaban, and dabigatran) that offer rapid oral anticoagulation without the need for routine monitoring or major food interactions, though they should be avoided in patients with mechanical heart valves.
- Overlapping Clinical Goals:
Across all classes, these agents function as vital anticoagulants carrying an inherent bleeding risk while sharing core therapeutic objectives in preventing and treating thrombosis, managing acute conditions like DVT PE, and achieving rapid therapeutic onset where applicable.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?